Macroaxis: Personalized Investing
Simple Personalized Investing

JNJ PFE NVS SNY Large Blend Moderate Software Hotels 
Benchmark SP 500  1,650   0.91  Index Moved Down -0.06% ...


Processing
Collecting data for MRK

Merck quote and profile

 
 Companies |  Insiders  | Dashboard  
     
47.16
  
STOCK
(0.17)  Macroaxis: -0.36 Down   0.36%  
Year To Date
37.0248.79
Last 1 Month(s)
44.9847.87
Trading Day 
46.647.16
May 25 2013 

Diversification Suggestion

Use Merck to protect against small markets fluctuations. The stock experiences normal downward trend and little activity
Analyze Merck Trend or Check current 30 days Merck correlation with market (S&P 500)
1 Month Beta 0.58  
Highest Price:  
Lowest Price:  
47.87  
44.98  
April 26 2013 
May 06 2013 
As returns on market increase, Merck returns are expected to increase less than the market. However during bear market, the loss on holding Merck will be expected to be smaller as well.
Merck   Co Inc Small BetaMerck Beta Legend
MRK United States NYSE
Merck Co Inc
Healthcare
Drug Manufacturers - Major
Benchmark S&P 500
http://www.merck.com
Contact Number: 908. 423. 1000
Currency: USD - US Dollar
Traded on New York Stock Exchange
    
Current Valuation143.67 B
Shares Outstanding3.02 B
Number of Shares Shorted28.5 M
Revenue46.21 B
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.00 % No Change  
 United States SP 500   0.06 % Macroaxis: 0.06 Moved Down  
 
 United States NYSE   0.25 % Macroaxis: 0.25 Moved Down  
 
 thisRed MRK MRK agains markets  0.36 % Macroaxis: 0.36 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Merck Leadership

Kenneth Frazier Chairman, CEO and Pres
Peter Kim Executive VP and President of Merck Research Laboratories, Ph.D
Willie Deese Executive Vice President and Presidentident - Merck Manufacturing Division
Mirian Graddick-Weir Executive Vice President - Human Resources

Merck Price and Market Media

The median price of Merck for the period between Thu, Apr 25, 2013 and Sat, May 25, 2013 is 46.37 with a coefficient of variation of 1.96. The daily time series for the period is distributed with a sample standard deviation of 0.91, arithmetic mean of 46.34, and mean deviation of 0.78. The Stock received substential amount of media coverage during this period.
Merck         SP 500
Price Growth (%)
 
1
Merck and Co. Inc. and Pfizer Enter Worldwide Collaboration ...04/30/2013Macroaxis: MarketWatch News
2
Merck and Co. Inc. Issues Fed Bring Down Dow05/02/2013Macroaxis: News
3
MERCK and CO. INC. Merck and Celebrity Chef Art Smith Cook U...05/08/2013Macroaxis: News
4
MERCK and CO. INC. Sanford Heisler Files 100m Discrimination...05/10/2013Macroaxis: News
5
Merck and Co. Inc. Big Payout Little Flexibility05/14/2013Macroaxis: News
6
MERCK and CO. INC. Merck Prices 6.5 Billion Debt Offering05/16/2013Macroaxis: News
7
MERCK and CO. INC. FDA Staff Merck Sleep Drug Effective but ...05/21/2013Macroaxis: News

Merck Summary

Merck Co Inc [MRK] is traded on New York Stock Exchange in USA. It is located in Whitehouse Station, NJ and employs 83,000 people. The company currently falls under 'Mega-Cap' category with total capitalization of 142.4 B. Merck Co Inc runs under Healthcare sector within Drug Manufacturers - Major industry. This company has 3.02 B outstanding shares of which 28.5 M shares are now shorted by investors with about 1.9 days to cover shorted positions.
Merck & Co., Inc. offer various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care solutions worldwide. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
Less
Than
16 %
 
Follow Merck with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Merck to your reader
 

Merck Research Report

Merck vs. Johnson

Correlation analysis and fundamentals comparison between Merck and Johnson Johnson

Merck Executives

Peter Kellogg CFO and Executive VP

Merck Directors

Thomas Glocer Independent Director
Thomas Cech Independent Director
William Harrison Lead Independent Director
Carlos Represas Independent Director
Peter Wendell Independent Director

Merck Fundamentals

Cash per Share vs Z Score
Current Asset vs Cash and Equivalents
Cash per Share vs Price to Book
Current Ratio vs Cash and Equivalents

Merck vs Competition

Merck vs. Johnson Johnson
Merck vs. Pfizer Inc
Merck vs. Novartis AG
Merck vs. Sanofi
Merck vs. GlaxoSmithKline plc
Merck vs. BristolMyers Squibb Company
Merck vs. AstraZeneca PLC
Merck vs. Eli Lilly and Company
Merck vs. Impax Laboratories Inc

Merck May 25 2013 Opportunity Range

Downside Deviation1.39
Information Ratio(0.13)
Maximum Drawdown6.0
Value At Risk(1.71)
Potential Upside1.33

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium